tyrosyltyrosine profile

Tyrosyltyrosine, also known as L-tyrosyl-L-tyrosine, is a dipeptide composed of two tyrosine residues linked by a peptide bond. It has been studied for its potential biological activities. Tyrosyltyrosine is a component of the active site of several enzymes, including tyrosinase and catechol oxidase. It is also a precursor to melanin, the pigment that gives skin, hair, and eyes their color. The synthesis of tyrosyltyrosine typically involves the condensation of two tyrosine molecules. The compound is then further modified to produce melanin. Tyrosyltyrosine has also been investigated for its potential antioxidant and anti-inflammatory properties. Some studies have shown that it can protect cells from damage caused by reactive oxygen species. Further research is needed to fully understand the biological effects and potential therapeutic applications of tyrosyltyrosine.'

tyrosyltyrosine: RN given refers to all-(L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tyrosyltyrosine : A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Tyr-Tyr : Tyrosyltyrosine in which each tyrosine residue has L-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	70590
CHEMBL ID	95286
CHEBI ID	60989
SCHEMBL ID	1574161
MeSH ID	M0125946

Synonym
chebi:60989 ,
CHEMBL95286 ,
peptide tyrosine-tyrosine
n-l-tyrosyl-l-tyrosine
h-tyr-tyr-oh
h-l-tyr-l-tyr-oh
l-tyr-l-tyr
di-l-tyrosine
melanin synthesized from tyr-tyr substrate catalyzed by tyrosinase for 40 hrs
l-tyrosine, l-tyrosyl-, mononer
(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
l-tyrosine, l-tyrosyl-, monomer
tyrosyltyrosine
(s)-2-[(s)-2-amino-3-(4-hydroxy-phenyl)-propionylamino]-3-(4-hydroxy-phenyl)-propionic acid
bdbm50081840
1050-28-8
tyr-tyr
l-tyrosyl-l-tyrosine
(2s)-2-[[(2s)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoate
l-tyrosine, n-l-tyrosyl-
SCHEMBL1574161
AKOS030525649
(s)-2-((s)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-(4-hydroxyphenyl)propanoic acid
mfcd00063044
Q27130548
tyrosyl tyrosine
F82259
MS-25280
CS-0064315
HY-114782

Excerpt	Reference	Relevance
" Here, we further investigate the effects of MGAT2 inhibition on (a) fat-induced gut peptide release and fat intake in normal mice and (b) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB)."	( Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob/ob mice fed on a high-fat diet. Adachi, R; Kitazaki, T; Maki, T; Mochida, T; Nakakariya, M; Sato, K; Take, K; Takekawa, S, 2020)	0.56

Excerpt	Relevance	Reference
" Bolus dosing significantly increased parameters of mucosal mass along the length of the small intestine in association with an increase in two hour accumulation of vincristine arrested metaphases in small intestinal crypts."	( Effects of bolus doses of fat on small intestinal structure and on release of gastrin, cholecystokinin, peptide tyrosine-tyrosine, and enteroglucagon. Bloom, SR; Ghatei, MA; Jenkins, AP; Thompson, RP, 1992)	0.28
" Comparisons performed among the dosing schedules indicated that dosing immediately before breakfast maximized the PD effects of LX4211 on both SGLT1 and SGLT2 inhibition."	( Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Banks, P; Boehm, KA; Frazier, K; Freiman, J; Ogbaa, I; Powell, D; Ruff, D; Sands, A; Turnage, A; Zambrowicz, B, 2013)	0.39
"This clinical study indicates that dosing of LX4211 immediately before breakfast maximized the PD effects of both SGLT1 and SGLT 2 inhibition and provided a convenient dosing schedule for future trials."	( Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Banks, P; Boehm, KA; Frazier, K; Freiman, J; Ogbaa, I; Powell, D; Ruff, D; Sands, A; Turnage, A; Zambrowicz, B, 2013)	0.39
"A 2-week parallel randomized clinical trial with an additional visit conducted 1 week after dosing termination."	( Sucralose Consumption over 2 Weeks in Healthy Subjects Does Not Modify Fasting Plasma Concentrations of Appetite-Regulating Hormones: A Randomized Clinical Trial. Aguilar-Salinas, CA; Almeda-Valdes, P; Brito-Córdova, GX; Gómez-Díaz, RA; Gómez-Pérez, FJ; Guillén-Pineda, LE; López-Carrasco, MG; Romo-Romo, A, 2020)	0.56

Role	Description
Mycoplasma genitalium metabolite	Any bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tyrosyltyrosine	A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 15 member 1	Homo sapiens (human)	IC50 (µMol)	60.0000	0.1800	0.1900	0.2000	AID266249
Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)	IC50 (µMol)	3.8000	3.8000	3.8000	3.8000	AID213702
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	60.0000	0.0002	0.6603	10.0000	AID266249
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
monoatomic ion transport	Solute carrier family 15 member 1	Homo sapiens (human)
protein transport	Solute carrier family 15 member 1	Homo sapiens (human)
peptide transport	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
proton transmembrane transport	Solute carrier family 15 member 1	Homo sapiens (human)
tyrosyl-tRNA aminoacylation	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
apoptotic process	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
response to starvation	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
peptide:proton symporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
tRNA binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
RNA binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
tyrosine-tRNA ligase activity	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
interleukin-8 receptor binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
protein binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
ATP binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
small molecule binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
brush border	Solute carrier family 15 member 1	Homo sapiens (human)
membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
nucleus	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
cytoplasm	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
cytosol	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
extracellular space	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
cytosol	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
nuclear body	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID266248	Ratio of %GSmax to EC50 for human PEPT1 activation	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266246	Activation of human PEPT1 expressed in MDCK cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID213702	Compound was tested for inhibition of Staphylococcus aureus tyrosyl tRNA Synthetase	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	Interaction of tyrosyl aryl dipeptides with S. aureus tyrosyl tRNA synthetase: inhibition and crystal structure of a complex.
AID266249	Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266247	Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (4.35)	18.7374
1990's	7 (10.14)	18.2507
2000's	11 (15.94)	29.6817
2010's	39 (56.52)	24.3611
2020's	9 (13.04)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	20 (27.78%)	5.53%
Reviews	7 (9.72%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (1.39%)	0.25%
Other	44 (61.11%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	3.41	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
ammonium hydroxide azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.	3.5	1	1	azane; gas molecular entity; mononuclear parent hydride	EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant
3-hydroxybutyric acid 3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.. 3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.	2.11	1	0	(omega-1)-hydroxy fatty acid; 3-hydroxy monocarboxylic acid; hydroxybutyric acid	human metabolite
glycine [no description available]	2.03	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	3.7	1	1	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
2,2'-azobis(2-amidinopropane) 2,2'-azobis(2-amidinopropane): water-soluble free-radical initiator	2.25	1	0	monoazo compound
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	1.98	1	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
racemetirosine alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)	4.39	1	1
thiorphan Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.	1.96	1	0	N-acyl-amino acid
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	2.05	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.05	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	4.41	1	1	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	1.96	1	0	N-acyl-amino acid
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	3.64	1	1	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.66	3	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.96	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	1.96	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.03	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.02	1	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
xylitol xylooligosaccharide: structure in first source. pentitol : An alditol obtained by reduction of any pentose.. xylooligosaccharide : An oligosaccharide comprised of xylose residues.	3.7	1	1
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	3.47	1	1	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
glycyl-glycyl-glycine glycyl-glycyl-glycine : A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence.	2.03	1	0	tripeptide zwitterion; tripeptide
glycylglycine [no description available]	2.03	1	0	dipeptide zwitterion; dipeptide	human metabolite
2,2-dichloroacetamide [no description available]	2.11	1	0
copper sulfate Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.. copper(II) sulfate : A metal sulfate compound having copper(2+) as the metal ion.	2.02	1	0	metal sulfate	emetic; fertilizer; sensitiser
substance p [no description available]	2	1	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
enkephalin, methionine Enkephalin, Methionine: One of the endogenous pentapeptides with morphine-like activity. It differs from LEU-ENKEPHALIN by the amino acid METHIONINE in position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.	1.96	1	0
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	1.96	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trichloroacetamide [no description available]	2.11	1	0
glycyl-glycyl-glycyl-glycine [no description available]	2.03	1	0
tyrosine methyl ester tyrosine methyl ester: RN given refers to (L)-isomer. methyl L-tyrosinate : An L-tyrosyl ester that is the methyl ester of L-tyrosine.	1.99	1	0	L-tyrosyl ester; methyl ester
trichlorosucrose trichlorosucrose: sweetness intensity roughly 600 times that of sucrose and is nonnutritive and noncaloric; largely unabsorbed in the gastrointestinal tract. sucralose : A disaccharide derivative consisting of 4-chloro-4-deoxy-alpha-D-galactopyranose and 1,6-dichloro-1,6-dideoxy-beta-D-fructofuranose units linked by a glycosidic bond.	3.64	1	1	disaccharide derivative; organochlorine compound	environmental contaminant; sweetening agent; xenobiotic
ubenimex ubenimex: growth inhibitor	1.96	1	0
leucylleucine Leu-Leu : A dipeptide formed from two L-leucine residues.	2.03	1	0	dipeptide; L-aminoacyl-L-amino acid zwitterion	human metabolite; Mycoplasma genitalium metabolite
phenylalanylphenylalanylamide [no description available]	2.03	1	0
Trp-Trp tryptophyltryptophan: an antigelation agent. Trp-Trp : A dipeptide formed from two L-tryptophan residues.	2.03	1	0	dipeptide	Mycoplasma genitalium metabolite
glycyltryptophan glycyltryptophan: RN given refers to (L)-isomer. Gly-Trp : A dipeptide formed from glycine and L-tryptophan residues.	2.03	1	0	dipeptide	metabolite
glycyltyrosine Gly-Tyr : A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.	2.03	1	0	dipeptide	metabolite
glycylleucine Gly-Leu : A dipeptide composed of glycine and L-leucine joined by a peptide linkage.	2.03	1	0	dipeptide zwitterion; dipeptide	metabolite
alanyltyrosine alanyltyrosine: tyrosine source; RN given refers to (L)-isomer. Ala-Tyr : A dipeptide composed of L-alanine and L-tyrosine joined by a peptide linkage.	2.46	2	0	dipeptide	metabolite
glycyl-l-phenylalanine glycylphenylalanine: RN given refers to (DL)-isomer. Gly-Phe : A dipeptide formed from glycine and L-phenylalanine residues.	2.03	1	0	dipeptide zwitterion; dipeptide	human metabolite; metabolite
glycylsarcosine glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.	2.03	1	0	dipeptide zwitterion; dipeptide
alanylphenylalanine alanylphenylalanine: RN given refers to (L-Ala-L-PheAla)-isomer	2.03	1	0	dipeptide	metabolite
tryptophylglycine Trp-Gly : A dipeptide formed from L-tryptophan and glycine residues.	2.03	1	0	dipeptide	metabolite
glycylaspartic acid glycylaspartic acid: RN given refers to (L)-isomer	2.03	1	0	dipeptide	metabolite
n-glycylglutamic acid N-glycylglutamic acid: RN given refers to (L)-isomer. Gly-Glu : A dipeptide formed from glycyl and L-glutamic acid residues.	2.03	1	0	dipeptide	metabolite
histidylglycine histidylglycine: RN given refers to all (L)-isomer. His-Gly : A dipeptide formed from L-histidine and glycine residues.	2.03	1	0	dipeptide	metabolite
valylvaline valylvaline: RN given refers to (L)-isomer. Val-Val : A dipeptide formed from two L-valine residues.	2.03	1	0	dipeptide	Mycoplasma genitalium metabolite
glycyl-leucyl-phenylalanine glycyl-leucyl-phenylalanine: an immunostimulatory peptide; RN given refer to all (L)-isomer	2.03	1	0	oligopeptide
lysyllysine lysyllysine: RN given refers to (L-Lys)-isomer. Lys-Lys : A dipeptide formed from two L-lysine residues.	2.47	2	0	dipeptide	Mycoplasma genitalium metabolite
aspartylglycine Asp-Gly : A dipeptide composed of L-aspartic acid and glycine joined by a peptide linkage.	2.03	1	0	dipeptide	metabolite
arginylarginine Arg-Arg : A dipeptide formed from two L-arginine residues.	2.03	1	0	dipeptide	Mycoplasma genitalium metabolite
n-valyltryptophan N-valyltryptophan: RN given refers to (L)-isomer	2.03	1	0	peptide
cyclo(tyrosyl-tyrosyl) cyclo(tyrosyl-tyrosyl): structure in first source. cyclo(tyrosyl-tyrosyl) : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by p-hydroxybenzyl groups.	2.15	1	0	2,5-diketopiperazines
prolylglutamic acid Pro-Glu : A dipeptide formed from L-proline and L-glutamic acid residues.	2.03	1	0	dipeptide	metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	1.98	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
glutamyl-glutamic acid glutamyl-glutamic acid: RN given for (L,L)-isomer. Glu-Glu : A dipeptide composed of two L-glutamic acid units joined by a peptide linkage.	2.03	1	0	dipeptide	Mycoplasma genitalium metabolite
phosphoramidon phosphoramidon: a membrane metallo-endopeptidase & endothelin-converting enzyme inhibitor; thermolysin inhibitor from culture filtrate of Streptomyces tanashiensis; structure. phosphoramidon : A dipeptide isolated from the cultures of Streptomyces tanashiensis.	1.96	1	0	deoxyaldohexose phosphate; dipeptide	bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
aspartyl-aspartic acid aspartyl-aspartic acid: do not confuse with cyclo(Asp-Asp). Asp-Asp : A dipeptide formed from two L-aspartic acid units.	2.03	1	0	dipeptide	Mycoplasma genitalium metabolite
glycosides [no description available]	4.39	1	1
n-glycylalanine Gly-Ala : A dipeptide formed from glycine and L-alanine residues.	2.03	1	0	dipeptide	metabolite
D-fructopyranose [no description available]	4.41	1	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.	2.03	1	0	dipeptide zwitterion; dipeptide	metabolite
glycyllysine glycyllysine: RN given refers to (L)-isomer. Gly-Lys : A dipeptide formed from glycine and L-lysine residues.	2.03	1	0	dipeptide	metabolite
gamma-linolenic acid gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed). gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.	1.98	1	0	linolenic acid; omega-6 fatty acid	human metabolite; mouse metabolite; plant metabolite
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	4.41	1	1	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.25	1	0	cysteinium	fundamental metabolite
alanyl-alanyl-alanine alanyl-alanyl-alanine: RN given refers to all (L)-isomer. Ala-Ala-Ala : A tripeptide composed of three L-alanine units joined by peptide linkages.	2.11	1	0	tripeptide	metabolite
alanylalanine L-alanyl-L-alanine : A dipeptide consisting of two L-alanine units joined by a peptide linkage.	2.03	1	0	dipeptide zwitterion; dipeptide	Mycoplasma genitalium metabolite
phenylalanylalanine phenylalanylalanine: RN given refers to (L)-isomer. Phe-Ala : A dipeptide formed from L-phenylalanine and L-alanine residues.	2.03	1	0	dipeptide zwitterion; dipeptide	metabolite
alanyltyrosine Tyr-Ala : A dipeptide formed from L-tyrosine and L-alanine residues.	2.03	1	0	dipeptide	metabolite
prolylglycine prolylglycine: RN given refers to (L)-isomer. L-prolylglycine : A dipeptide consisting of glycine having an L-prolyl group attached to its alpha-amino nitrogen.	2.03	1	0	dipeptide zwitterion; dipeptide
arginyllysine Arg-Lys : A dipeptide formed from L-arginyl and L-leucine residues.	2.03	1	0	dipeptide	metabolite
phenylalanylglycine phenylalanylglycine: RN given refers to (DL)-isomer. Phe-Gly : A dipeptide formed from L-phenylalanine and glycine residues.	2.03	1	0	dipeptide	metabolite
histidylhistidine histidylhistidine: RN given for L-,L-isomer	2.03	1	0	dipeptide	Mycoplasma genitalium metabolite
lysylglutamic acid lysylglutamic acid: a geroprotective agent. Lys-Glu : A dipeptide formed from L-lysine and L-glutamic acid residues.	2.03	1	0	dipeptide	metabolite
Ala-Lys Ala-Lys : A dipeptide obtained by formal condensation of the carboxy group of L-alanine with the alpha-amino group of L-lysine.	2.03	1	0	dipeptide	marine metabolite
valyl-valyl-valine [no description available]	2.03	1	0	peptide
lysylglycine lysylglycine: structure in first source. Lys-Gly : A dipeptide formed from L-lysine and glycine residues.	2.03	1	0	dipeptide	metabolite
glycylhistidine glycylhistidine: RN given refers to (L)-isomer. Gly-His : A dipeptide composed of glycine and L-histidine joined by a peptide linkage.	2.03	1	0	dipeptide zwitterion; dipeptide	metabolite
prolyl-serine Pro-Ser : A dipeptide formed from L-proline and L-serine residues.	2.03	1	0	dipeptide	metabolite
sitagliptin phosphate Sitagliptin Phosphate: A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.	2.17	1	0
prolyl-proline Pro-Pro : A dipeptide formed from two L-proline residues.	2.03	1	0	dipeptide	human urinary metabolite; Mycoplasma genitalium metabolite
cholecystokinin Cholecystokinin: A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.	9.83	12	4
motilin Motilin: A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.	2	1	0
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	2.91	4	0
glucagon Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.	5.23	6	2	peptide hormone
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	4.56	4	0
pancreastatin pancreastatin: A 49 residue post-translational fragment of chromogranin A that inhibits insulin secretion; amino acid sequence given in first source; the 49-amino acid peptide is from pig; human pancreastatin has 52 amino acids (hCgA 250-310) ; see also record for human pancreastatin	1.98	1	0
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	13.84	31	16
c-peptide C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.	4.84	2	1
aspartyltyrosine [no description available]	2.13	1	0
caseins Caseins: A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.	3.5	1	1
glucagon-like peptide 2 Glucagon-Like Peptide 2: A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.	2.41	1	0
oxyntomodulin Glucagon-Like Peptides: Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.	5.06	5	0
peptide yy Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.. peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence.	6.14	3	2
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	10.7	13	7

Condition	Relationship Strength	Studies	Trials
Polycystic Ovarian Syndrome [description not available]	2.59	2	0
Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.	2.59	2	0
Diabetes Mellitus, Adult-Onset [description not available]	4.13	5	0
Morbid Obesity [description not available]	3.57	2	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	4.13	5	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.41	1	0
Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.	3.57	2	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	11.7	18	5
Weight Gain Increase in BODY WEIGHT over existing weight.	2.25	1	0
Hyperphagia Ingestion of a greater than optimal quantity of food.	4.99	2	1
Insulin Sensitivity [description not available]	3.64	1	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	3.64	1	1
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	8.25	6	4
Weight Reduction [description not available]	4.17	3	0
Weight Loss Decrease in existing BODY WEIGHT.	4.17	3	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	3.56	1	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	3.56	1	1
Cancer of Liver [description not available]	2.11	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.11	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.11	1	0
Hepatoblastoma A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)	2.11	1	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	4.41	1	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	5.83	2	2
Cancer of Pancreas [description not available]	2.1	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.1	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.11	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.11	1	0
Indigestion [description not available]	2.13	1	0
Dyspepsia Impaired digestion, especially after eating.	2.13	1	0
Leanness [description not available]	2.05	1	0
Impaired Glucose Tolerance [description not available]	2.06	1	0
Apnea, Obstructive Sleep [description not available]	2.06	1	0
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.06	1	0
Sleep Apnea, Obstructive A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)	2.06	1	0
Inborn Urea Cycle Disorder [description not available]	2.07	1	0
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	2.07	1	0
Urea Cycle Disorders, Inborn Rare congenital metabolism disorders of the urea cycle. The disorders are due to mutations that result in complete (neonatal onset) or partial (childhood or adult onset) inactivity of an enzyme, involved in the urea cycle. Neonatal onset results in clinical features that include irritability, vomiting, lethargy, seizures, NEONATAL HYPOTONIA; RESPIRATORY ALKALOSIS; HYPERAMMONEMIA; coma, and death. Survivors of the neonatal onset and childhood/adult onset disorders share common risks for ENCEPHALOPATHIES, METABOLIC, INBORN; and RESPIRATORY ALKALOSIS due to HYPERAMMONEMIA.	2.07	1	0
Altitude Hypoxia Low ambient oxygen tension associated with ALTITUDE.	2.08	1	0
Altitude Sickness Multiple symptoms associated with reduced oxygen at high ALTITUDE.	2.08	1	0
Convalescence The period of recovery following an illness.	4.39	1	1
Binge Eating [description not available]	4.39	1	1
Bulimia Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as ox hunger.	4.39	1	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.96	1	0

tyrosyltyrosine

Description

Cross-References

Synonyms (30)

Research Excerpts

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Biological Processes (9)

Molecular Functions (11)

Ceullar Components (9)

Bioassays (5)

Research

Studies (69)

Market Indicators

Research Demand Index: 10.72

Study Types